{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:29:56Z","timestamp":1782149396081,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11523-021-00842-1","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T03:34:29Z","timestamp":1633750469000},"page":"847-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"842_CR1","unstructured":"American Cancer Society. Key statistics for ovarian cancer. 2021. https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html. Accessed 2 Sept 2021."},{"issue":"4","key":"842_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.annonc.2021.01.006","volume":"32","author":"G Carioli","year":"2021","unstructured":"Carioli G, Malvezzi M, Bertuccio P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol. 2021;32(4):478\u201387.","journal-title":"Ann Oncol"},{"key":"842_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3\u201314.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"842_CR4","unstructured":"Genentech. Avastin\u00ae (bevacizumab): US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/. Accessed 2 Sept 2021."},{"issue":"4","key":"842_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"842_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"842_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40661-017-0039-8","volume":"4","author":"MK Frey","year":"2017","unstructured":"Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract. 2017;4:4.","journal-title":"Gynecol Oncol Res Pract"},{"issue":"3","key":"842_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-019-00347-4","volume":"33","author":"SA Cook","year":"2019","unstructured":"Cook SA, Tinker AV. PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs. 2019;33(3):255\u201373.","journal-title":"BioDrugs"},{"key":"842_CR9","unstructured":"European Medicines Agency. Lynparza\u00ae (olaparib): EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/. Accessed 2 Sept 2021."},{"key":"842_CR10","unstructured":"AstraZeneca. Lynparza\u00ae (olaparib): US prescribing information. 2020. https:\/\/accessdata.fda.gov\/. Accessed 2 Sept 2021."},{"issue":"2","key":"842_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40259-015-0125-6","volume":"29","author":"JE Frampton","year":"2015","unstructured":"Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015;29(2):143\u201350.","journal-title":"BioDrugs"},{"issue":"6","key":"842_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11523-018-0606-x","volume":"13","author":"Y-A Heo","year":"2018","unstructured":"Heo Y-A, Dhillon S. Olaparib tablet: a review in ovarian cancer maintenance therapy. Targeted Oncol. 2018;13(6):801\u20138.","journal-title":"Targeted Oncol"},{"issue":"26","key":"842_CR13","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"842_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"30","key":"842_CR15","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1200\/JCO.20.00799","volume":"38","author":"P DiSilvestro","year":"2020","unstructured":"DiSilvestro P, Colombo N, Scambia G, et al. Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. J Clin Oncol. 2020;38(30):3528\u201337.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"842_CR16","first-page":"A76","volume":"30","author":"N Colombo","year":"2020","unstructured":"Colombo N, Bradley W, Moore K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III SOLO1 study [abstract no. 392]. Int J Gynecol Cancer. 2020;30(Suppl 4):A76\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"842_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","volume":"22","author":"M Friedlander","year":"2021","unstructured":"Friedlander M, Moore KN, Colombo N, et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021;22(5):632\u201342.","journal-title":"Lancet Oncol"},{"issue":"Suppl. 4","key":"842_CR18","doi-asserted-by":"publisher","first-page":"S613","DOI":"10.1016\/j.annonc.2020.08.950","volume":"31","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, Moore K, Colombo N, et al. Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1 [abstract no. 811MO]. Ann Oncol. 2020;31(Suppl. 4):S613.","journal-title":"Ann Oncol"},{"key":"842_CR19","doi-asserted-by":"crossref","unstructured":"Bradley W. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1 [abstract no. 10520]. In: SGO Annual Meeting on Women's Cancer. 2021.","DOI":"10.1016\/S0090-8258(21)00694-6"},{"issue":"Suppl 4","key":"842_CR20","doi-asserted-by":"publisher","first-page":"S1163","DOI":"10.1016\/j.annonc.2020.08.2263","volume":"31","author":"A Gonz\u00e1lez Martin","year":"2020","unstructured":"Gonz\u00e1lez Martin A, Tazi Y, Heitz F, et al. Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1\/ENGOT-ov25 trial [abstract no. LBA33]. Ann Oncol. 2020;31(Suppl 4):S1163\u20134.","journal-title":"Ann Oncol"},{"key":"842_CR21","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E. Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1\/ENGOT-ov25 trial [abstract no. 10543]. In: SGO Annual Meeting on Women's Cancer. 2021.","DOI":"10.1016\/S0090-8258(21)00695-8"},{"issue":"Suppl 3","key":"842_CR22","first-page":"A13","volume":"30","author":"P Harter","year":"2020","unstructured":"Harter P, Petran D, Scambia G, et al. Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial [abstract no. IGCS20_1207]. Int J Gynecol Cancer. 2020;30(Suppl 3):A13\u20134.","journal-title":"Int J Gynecol Cancer"},{"key":"842_CR23","doi-asserted-by":"publisher","unstructured":"Colombo N, Moore K, Scambia G, et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021. https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.016.","DOI":"10.1016\/j.ygyno.2021.07.016"},{"key":"842_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152\u201360.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"842_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"842_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672\u2013705.","journal-title":"Ann Oncol"},{"key":"842_CR27","unstructured":"National Institute for Health and Care Excellence. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. 2013. https:\/\/www.nice.org.uk\/. Accessed 2 Sept 2021."},{"issue":"30","key":"842_CR28","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1200\/JCO.20.01924","volume":"38","author":"WP Tew","year":"2020","unstructured":"Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468\u201393.","journal-title":"J Clin Oncol"},{"key":"842_CR29","unstructured":"National Institute for Health and Care Excellence. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. 2019. https:\/\/www.nice.org.uk\/. Accessed 2 Sept 2021."},{"key":"842_CR30","unstructured":"National Institute for Health and Care Excellence. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. 2021. https:\/\/www.nice.org.uk\/. Accessed 2 Sept 2021."},{"key":"842_CR31","unstructured":"National Institute for Health and Care Excellence. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. 2021. https:\/\/www.nice.org.uk\/. Accessed 2 Sept 2021."},{"issue":"Suppl 1","key":"842_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2020.06.038","volume":"159","author":"IB Vergote","year":"2020","unstructured":"Vergote IB, Moore KN, Hettle R, et al. Population adjusted indirect comparison of the SOLO1 and PAOLA-1\/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III\/IV ovarian cancer with BRCA mutation [abstract no. 35]. Gynecol Oncol. 2020;159(Suppl 1):19\u201320.","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"842_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2020.05.186","volume":"159","author":"DRG Muston","year":"2020","unstructured":"Muston DRG, McLaurin K, Hettle R, et al. Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1\/2 mutation: a United States payer perspective [abstract no. 298]. Gynecol Oncol. 2020;159(Suppl 1):140\u20131.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"842_CR34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.clinthera.2020.04.015","volume":"42","author":"P Armeni","year":"2020","unstructured":"Armeni P, Borsoi L, Fornaro G, et al. Cost-effectiveness and net monetary benefit of olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1\/2-mutated ovarian cancer in the Italian National Health Service. Clin Ther. 2020;42(7):1192-209.e12.","journal-title":"Clin Ther"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00842-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:30:50Z","timestamp":1637753450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00842-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"2 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia Paik is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}